Novel Agents in Relapsed/Refractory T-Cell Lymphoma

The chapter delves into the use of novel agents in treating relapsed/refractory T-cell lymphoma, highlighting the challenges and differences in efficacy across histologic subtypes, particularly addressing the complexities with anaplastic large cell lymphoma. It discusses strategies like combining hypomethylating agents and HDAC inhibitors for inducing complete remission and potentially preparing patients for allotransplant. Additionally, the chapter emphasizes the importance of appropriate trial design for patient selection and sequencing in untreated PTCL cases to enhance drug response.